Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

Annals of neurology·2022
Same author

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Multiple sclerosis and related disorders·2016
Same author

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.

Expert review of neurotherapeutics·2015
Same author

Primary progressive multiple sclerosis.

Continuum (Minneapolis, Minn.)·2012
Same author

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Therapeutic advances in neurological disorders·2010
Same author

B cells as a target of immune modulation.

Annals of Indian Academy of Neurology·2010
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Progressive multiple sclerosis: characteristics and management.

Kathleen Hawker1

  • 1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. hawkerks@lilly.com

Neurologic Clinics
|March 29, 2011
PubMed
Summary
This summary is machine-generated.

Progressive multiple sclerosis (MS) subtypes may show early disease progression. Some progressive MS patients might benefit from disease-modifying drugs, challenging the notion that neurodegeneration is irreversible.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Related Experiment Videos

Last Updated: Jun 3, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Area of Science:

  • Neurology
  • Neuroimmunology
  • Radiology

Background:

  • Progressive multiple sclerosis (MS) encompasses secondary progressive MS, primary progressive MS, and progressive relapsing MS.
  • Limited approved treatments exist for progressive MS subtypes, often attributed to irreversible neurodegeneration.
  • Current treatments primarily target inflammation, which may not address the core pathology of progressive MS.

Purpose of the Study:

  • To review magnetic resonance imaging (MRI) and clinical data regarding disease progression in multiple sclerosis.
  • To investigate the potential for disease-modifying drugs to impact progression in specific subsets of progressive MS patients.
  • To challenge the paradigm that neurodegeneration in progressive MS is untreatable.

Main Methods:

  • Review of existing magnetic resonance imaging (MRI) studies.
  • Analysis of clinical trial data for progressive MS phenotypes.
  • Synthesis of evidence on treatment response in different MS subtypes.

Main Results:

  • Evidence suggests that MS progression can initiate early in the disease course.
  • Specific patient subsets within progressive MS populations demonstrate responsiveness to disease-modifying drugs.
  • Neurodegeneration in progressive MS may not be entirely irreversible or untreatable.

Conclusions:

  • Early detection of progression in MS is crucial.
  • Disease-modifying therapies hold potential for specific progressive MS patient groups.
  • Further research into targeted treatments for neurodegeneration in MS is warranted.